Krystal Biotech Inc(KRYS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 26 at 4:02 PM ET (Korea 10/27 05:02)
Full metrics table
| Index | RUT | P/E | 39.31 | EPS (ttm) | 7.98 | Insider Own | 12.26% | Shs Outstand | 29.6M | Perf Week | -2.06% |
| Market Cap | 9.28B | Forward P/E | 34.79 | EPS next Y | 22.37% | Insider Trans | -3.37% | Shs Float | 26.0M | Perf Month | -9.3% |
| Enterprise Value | 8.45B | PEG | 1.51 | EPS next Q | 1.82 | Inst Own | 99.45% | Short Float | 13.38% | Perf Quarter | -13.88% |
| Income | 0.24B | P/S | 21.08 | EPS this Y | 7.71% | Inst Trans | 3.78% | Short Ratio | 11.96 | Perf Half Y | 15% |
| Sales | 0.44B | P/B | 6.83 | EPS next 5Y | 23.07% | ROA | 18.3% | Short Interest | 3.48M | Perf YTD | 27.22% |
| Book/sh | 45.92 | P/C | 10.98 | EPS past 3/5Y | - | ROE | 20.12% | 52W High | -18% ($382.54) | Perf Year | 68.52% |
| Cash/sh | 28.57 | P/FCF | 36.02 | Sales past 3/5Y | - | ROIC | 17.67% | 52W Low | 71.15% ($183.26) | Perf 3Y | 165.79% |
| Dividend Est. | - | EV/EBITDA | 41.33 | EPS Y/Y TTM | 62.39% | Gross Margin | 93.31% | Volatility(W/M) | 2.67% 3.18% | Perf 5Y | 476.16% |
| Dividend TTM | - | EV/Sales | 19.18 | Sales Y/Y TTM | 22.63% | Oper. Margin | 44.89% | ATR (14) | 10.4 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 7.96 | EPS Q/Q | 38.64% | Profit Margin | 54.82% | RSI (14) | 39.57 | Recom | 1.23 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.32 | Sales Q/Q | 24.14% | SMA20 | -3.55% ($325.2) | Beta | 0.57 | Target Price | $395.44 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/11/2 | SMA50 | -7.33% ($338.47) | Rel Volume | 0.77 | Prev Close | $311.5 |
| Employees | 295 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | 5.23% -1.41% | SMA200 | 1.96% ($307.63) | Avg Volume(3M) | 0.29M | Price | $313.66 |
| IPO | 2017/9/20 | Option/Short | Yes/Yes | Trades | 7258 | Volume | 223,765 | Change | 0.69% |
A U.S. biotech company specializing in gene therapy, focused on developing and commercializing gene therapies for inherited rare skin diseases. Its performance hinges on the sales of its already approved commercial product, label expansions, and the development of new drugs.
Over the past 1 year, roughly in the middle
18% below its 1-year high.
Traded less than usual. That is 77% of its average volume.
Next earnings report: November 2
6 days to go.
KRYS makes money exceptionally well
Of every $100 in sales, $44.89 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +7.7% this year.
Tap to view numbers
The price is about the industry average
For a company expected to earn $100 next year, you would pay $3,479. Peers typically go for $2,544. It is about in line with its own 3-year average.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +476.2%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership is about average
Institutions hold 99.5%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #27 of 594 in the industry
Based on market cap of $9B.
PCVX#25 Vaxcyte Inc $9B PER - 
CORT#26 Corcept Therapeutics Inc $9B PER 208.1 KRYS#27 Krystal Biotech Inc $9B PER 39.3 
CAI#28 Caris Life Sciences Inc $9B PER 87.2 
PTGX#29 Protagonist Therapeutics Inc $9B PER 135.3 
FAQ
What kind of company is KRYS?
KRYS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of KRYS?
The market cap of KRYS is approximately $9.3B, ranking 953 within its sector.
What is the P/E ratio of KRYS?
KRYS has a P/E ratio of approximately 39.3x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for KRYS?
KRYS has recorded a 52-week high of $382.54 and a low of $183.26.
